New pain shot studied in seniors after keyhole surgery
NCT ID NCT07353983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a new pain medicine called Anrikefon works in older adults after laparoscopic belly surgery. Thirty people aged 65 and older will receive the drug and have their blood tested to measure drug levels. The goal is to understand how the drug behaves in older bodies and how well it controls pain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 65 years, gender unrestricted; * American Society of Anesthesiologists (ASA) classification I-III; * 18 kg/m2 ≤ BMI \< 30 kg/m2; * Undergoing elective general anesthesia for laparoscopic surgery and expected to experience mild to moderate postoperative pain; * Agree to participate in this trial and voluntarily sign the informed consent form. Exclusion Criteria: * There is a history or evidence of any of the following diseases before screening:1) History of cardiovascular diseases: Uncontrolled hypertension (systolic blood pressure ≥160 MMHG and/or diastolic blood pressure ≥90mmHg), as well as a history of cardiovascular diseases evaluated by the researcher as unsuitable for participation in the study, such as severe arrhythmia, heart failure, acute myocardial ischemia, unstable angina pectoris, myocardial infarction, II-III degree atrioventricular block, etc.2) Respiratory system history: Severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, and other respiratory system histories assessed by the researcher as unsuitable for participation in the study;3) History of neurological and mental system diseases: Craniocerebral injury, intracranial hypertension, schizophrenia, mania, cognitive dysfunction, etc., evaluated by the researcher as unsuitable for participation in the study;4) History of digestive system diseases: Suffering from intestinal obstruction or other digestive system diseases that the researcher deems may cause nausea and vomiting;5) Accompanied by a clear history of chronic dizziness, or clearly diagnosed vestibular dysfunction other than motion sickness (including but not limited to: peripheral vestibular syndrome, central vestibular syndrome, etc.);6) Tumor patients who have received chemotherapy and/or radiotherapy within 4 weeks prior to being informed. * It is expected that tracheal intubation will continue after the operation or a nasal or oral gastric tube will need to be inserted. * Known to be allergic or contraindicated to opioid drugs and other anesthetics and antiemetic drugs that may be used during the trial; * Within 3 months prior to screening, there is a history of drug abuse, or continuous use of opioid analgesics for more than 10 days for any reason; * Abnormal liver and kidney functions:1) Prothrombin time (PT) is prolonged by more than 3 seconds beyond the upper limit of the normal value;2) Alanine aminotransferase and/or aspartate aminotransferase \> 2×ULN;3) Total bilirubin \> 1.5×ULN;4) Glomerular filtration rate (eGFR) \< 60 mL/min. * Have participated in any clinical researchers within the three months prior to the screening; * Pregnant and lactating women who have plans to become pregnant during the study period or within 3 months after the study ends; * Subjects who the researchers consider to have any other factors that make them unsuitable for participating in this clinical study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Postoperative pain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two nerve blocks go head to head for chest surgery pain
- Can a Nurse's confidence ease a Patient's postoperative pain?
- Antidepressant may double as pain reliever after gallbladder surgery
- Nerve blocks put to the test for breast surgery pain
- A Non-Opioid pain drug takes aim at Surgery's opioid problem
- Can a nerve block stop pain months after hysterectomy?